This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| imipramine | |
|---|---|
| Drug name | Imipramine |
| Mechanism | Tricyclic antidepressant |
imipramine Imipramine is a tricyclic antidepressant developed in the mid‑20th century and used for mood and anxiety disorders. It has been studied and prescribed across clinical settings involving psychiatry and primary care in countries such as the United States, United Kingdom, and Germany. Research into imipramine intersected with work by figures and institutions including Julius Axelrod, Roland Kuhn, Eli Lilly and Company, and National Institutes of Health.
Imipramine is primarily indicated for major depressive disorder and has recognized applications in panic disorder and chronic enuresis in children when managed by pediatric teams. Clinical guidelines from bodies like the American Psychiatric Association, National Institute for Health and Care Excellence, and national ministries of health reference trials conducted at centers including Mayo Clinic, Johns Hopkins Hospital, and the Karolinska Institutet. Controlled studies compared imipramine to agents such as fluoxetine, sertraline, amitriptyline, and clomipramine, and to nonpharmacological interventions evaluated at institutions like Massachusetts General Hospital and McLean Hospital.
Use is contraindicated in individuals with recent myocardial infarction and in those taking monoamine oxidase inhibitors marketed by companies such as Pfizer and Roche. Prescribers consider comorbidities encountered at centers such as Cleveland Clinic and Mount Sinai Hospital, and consult formularies from agencies like the Food and Drug Administration and European Medicines Agency. Special caution is warranted in populations served by pediatric departments at Boston Children's Hospital, geriatric services at Guy's and St Thomas' NHS Foundation Trust, and in pregnancy clinics at Charité – Universitätsmedizin Berlin due to teratogenicity and perinatal risk reports.
Common adverse effects documented in multicenter trials led by investigators affiliated with Harvard Medical School, Stanford University School of Medicine, and Oxford University include anticholinergic symptoms, orthostatic hypotension, and weight changes. Serious events reported to pharmacovigilance systems at World Health Organization, European Medicines Agency, and U.S. Food and Drug Administration include cardiac arrhythmias, seizures, and serotonin syndrome when combined with serotonergic agents such as triptans developed by companies like GlaxoSmithKline and AstraZeneca. Overdose management protocols from emergency departments at Royal Infirmary of Edinburgh and Toronto General Hospital emphasize activated charcoal and cardiac monitoring.
Imipramine's mechanism involves inhibition of neurotransmitter reuptake and modulation of receptor systems studied in laboratories at Salk Institute, Max Planck Institute, and Cold Spring Harbor Laboratory. It primarily inhibits norepinephrine and serotonin transporters examined in assays used at Centers for Disease Control and Prevention and research programs funded by Wellcome Trust. Imipramine also antagonizes histaminergic, cholinergic, and adrenergic receptors characterized in receptor mapping studies at Columbia University Irving Medical Center and University of California, San Francisco.
Pharmacokinetic profiling has been performed in clinical pharmacology units at National Institutes of Health Clinical Center, Vanderbilt University Medical Center, and John Radcliffe Hospital. Imipramine is absorbed orally, undergoes hepatic metabolism involving cytochrome P450 isoforms such as CYP2D6 and CYP2C19 noted in pharmacogenetics research at International HapMap Project collaborators, and produces active metabolites monitored in laboratories at Mount Sinai School of Medicine. Clearance, half‑life, and plasma protein binding parameters inform dosing strategies taught in curricula at University of Toronto Faculty of Medicine and University of Sydney.
Development traces to mid‑20th century psychopharmacology with contributions from pharmaceutical firms and investigators including Geigy, Janssen Pharmaceutica, and clinical pioneers like Pierre Deniker and Jean Delay. Early trials occurred alongside studies of contemporaneous agents such as chlorpromazine and imipramine-era competitors noted in archives at Wellcome Library and the National Library of Medicine. Regulatory approvals were secured through agencies like the U.S. Food and Drug Administration following submissions based on datasets from hospitals including Bellevue Hospital and research centers at University College London.
Imipramine has been referenced in medical education at institutions such as Yale School of Medicine and in public health policy debated by stakeholders including World Health Organization committees and national formularies in Canada and Australia. Its availability, generic manufacturing, and patent history involved corporations such as Bristol-Myers Squibb and generic producers in markets regulated by the European Commission. Discussions about access, cost, and prescribing patterns have engaged advocacy groups and professional organizations like the American Medical Association and Royal College of Psychiatrists.
Category:Tricyclic antidepressants